Carton Packaging Market Size to Worth USD 316.10 Bn by 2032
May 07, 2024 07:20 ET
|
Precedence Research
Ottawa, May 07, 2024 (GLOBE NEWSWIRE) -- The global carton packaging market size was valued at USD 190.31 billion in 2023 and is predicted to hit around USD 297.64 billion by 2031, a study published...
Draganfly Unveils New NDAA Compliant “FlexForce” Modular FPV System Following US Military Demonstrations & Training
May 07, 2024 07:15 ET
|
Draganfly Inc
Draganfly’s FlexForce modular FPV system is available to Defense & Government users only San Diego, CA., May 07, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A)...
BioPorto A/S Appoints President and CEO of BioPorto Inc.
May 07, 2024 07:10 ET
|
BioPorto A/S
May 7, 2024News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company)...
Glycomics Market to reach $4.82 billion by 2031, at a CAGR of 13.5%, says Coherent Market Insights
May 07, 2024 07:07 ET
|
CMI
Burlingame, May 07, 2024 (GLOBE NEWSWIRE) -- The Global glycomics market is estimated to be valued at USD 1.99 Bn in 2024 and is expected to reach USD 4.82 Bn by 2031, growing at a compound annual...
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024 07:05 ET
|
uniQure Inc.
uniQure announces first quarter 2024 results
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) ...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024 07:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:01 ET
|
Prelude Therapeutics, Inc.
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at...
First Watch Restaurant Group, Inc. Reports Strong Q1 2024 Financial Results
May 07, 2024 07:00 ET
|
First Watch Restaurant Group, Inc.
Total revenues increased 14.7%; same-restaurant sales growth of 0.5%*Income from operations margin of 5.1% and restaurant level operating profit margin of 20.8%Net income of $7.2 million and Adjusted...
BioCryst to Present at Upcoming Investor Conferences
May 07, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: Citizens JMP...